Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16106
Title: Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
Authors: Yudi, MB;Eccleston, David;Andrianopoulos, Nick;Farouque, Omar;Duffy, Stephen J;Brennan, Angela;Reid, Christopher M;Clark, David J;Ajani, Andrew E
Institutional Author: Melbourne Interventional Group
Issue Date: Oct-2016
EDate: 2015-10-01
Citation: Internal Medicine Journal 2015; 45(1): 1032-1037
Abstract: BACKGROUND: Although dual antiplatelet therapy is the standard of care in non-ST-segment elevation acute coronary syndromes (NSTEACS), it remains unclear when a second antiplatelet agent should be initiated. We sought to assess the safety and efficacy of pre-treatment with clopidogrel in patients with NSTEACS undergoing percutaneous coronary intervention (PCI). METHODS: We analysed baseline clinical and procedural characteristics of 6817 patients with NSTEACS who underwent PCI from the Melbourne Interventional Group registry from 2005 to 2012. Patients were included in the pre-treatment group if clopidogrel was administered prior to cardiac catheterisation. We assessed 30-day mortality, myocardial infarction (MI) and major adverse cardiovascular events. The safety endpoint was in-hospital bleeding. RESULTS: Of the 6817 patients, only 2951 (43%) received pre-treatment with clopidogrel. Patients in the pre-treatment group were more likely to present with unstable angina (70.8% vs 68.2%, P = 0.02) and have a history of MI (35.6% vs 23.6%, P < 0.01) but were less likely to have PCI within 24 h of admission (17.2% vs 25.2%, P < 0.01). There was no difference between the groups in 30-day mortality (0.9% vs 1.4%, P = 0.06), MI (2.0% vs 2.2%, P = 0.52) or major adverse cardiovascular event (3.7% vs 4.2%, P = 0.25). There was no difference in bleeding complications (1.9% vs 1.9%, P = 0.94). CONCLUSIONS: Pre-treatment with dual antiplatelet therapy in NSTEACS is not routine clinical practice in Australia. Pre-treatment appears safe but is not associated with improved short-term clinical outcomes.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16106
DOI: 10.1111/imj.12818
PubMed URL: http://www.ncbi.nlm.nih.gov/pubmed/26013065
Type: Journal Article
Subjects: NSTEACS
PCI
Clopidogrel
Pre-treatement
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.